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countries, range from $3,200-$18,000 per OA patient (excluding surgeries).
In addition, costs associated with side effects of currently available drugs
(e.g. NSAID-related serious GI event) were also found to be signiﬁcant.
Conclusions: Based on the ﬁndings of this literature review, the burden of
OA pain is signiﬁcant. There appears to be a great unmet need for new
innovative treatments that can signiﬁcantly reduce pain without the sides
effects associated with currently available treatment options and/or drugs
which may delay progression of disease.
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CONTROLS REVEALS NOVEL AND POTENTIALLY FUNCTIONAL RARE
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Purpose: We have assessed whether rare DNA variants in a gene already
known to be associated with knee and hip osteoarthritis (OA) contribute
to OA susceptibility. The selected gene is GDF5 (growth and differentiation
factor 5), which harbours a single nucleotide polymorphism, rs143383,
in its 5’ untranslated region that shows very robust association to OA in
European and Asian populations. The risk allele of this SNP mediates a small
decrease in GDF5 expression. These results indicate that polymorphism in
this gene of small singular impact are important for OA development and
suggest that rarer but more disruptive variants may have greater effects on
gene function and therefore OA susceptibility.
Methods: Three groups of patients and controls were studied from the
UK, Spain and Greece. There were 992 patients (502 British, 264 Spanish
and 226 Greek) that had each undergone a total knee or a total hip joint
replacement due to severe primary OA and 944 controls (460 British, 294
Spanish and 190 Greek). In the Spanish and Greek cohorts the search for
rare variants focussed on the two exons of GDF5 and was performed by
Sanger sequencing after PCR ampliﬁcation. The Polyphred software was
then used to align sequences and to identify DNA changes. The UK search
encompassed the two exons as well as both untranslated regions and
100bp of the proximal promoter of the gene. Sanger sequencing after PCR
ampliﬁcation was also performed, with the SeqScape software used to
identify DNA changes.
Results: In the UK cohort we discovered ﬁve novel rare variants in GDF5,
four in control individuals and one in a case. One of the variants, identiﬁed
in a control, is located 40 base pairs upstream of the transcriptional
start site and is predicted to interfere with a highly conserved SOX9
transcription factor binding site. Three of the remaining variants were
found in exon 2, all in control individuals, one of which is predicted to
cause a non-conservative substitution of a highly conserved threonine to
an arginine. The ﬁnal variant was a synonymous substitution in exon 1
detected in a female patient with knee OA. Only a synonymous substitution
was discovered in the Spanish or Greek samples, in a control individual.
Conclusions: Our deep-sequencing analysis of over 1900 OA cases and
controls from northern and southern Europe has identiﬁed several novel
rare variants in the OA-associated gene GDF5. The effects of these variants
upon GDF5 expression and protein structure will now be investigated using
luciferase assays, in-vitro splicing studies and protein modeling to discover
whether these alleles are potentially protective, harmful or neutral to OA
susceptibility.
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Purpose: Several lines of evidence suggest that estrogens inﬂuence the
development of osteoarthritis (OA). The aim of this study was to explore
the genetic and functional association of two common polymorphisms from
within the aromatase (CYP19A1) and estrogen receptor α (ESR1) genes with
severe OA of the lower limbs.
Methods: The rs1062033 (CYP19A1) and rs2234693 (ESR1) single nu-
cleotide polymorphisms (SNPs) were genotyped in 5,479 individuals (3,098
patients with hip or knee OA ascertained by the need for joint replacement
surgery due to severe primary OA, and 2,381 controls) from three centres
in Spain and one centre in the UK. Expression of CYP19A1 and ESR1
was measured in femoral bone RNA samples from a group of patients
by real-time quantitative PCR and was subsequently stratiﬁed by donor
genotype at rs1062033 and rs2234693.
Results: In the global analysis, both polymorphisms were associated with
OA, but there was a signiﬁcant sex interaction. The GG genotype at
rs1062033 (a C/G transversion SNP) was associated with an increased risk
of knee OA in women (OR 1.23; p=0.04). The CC genotype at rs2234693
(a C/T transition SNP) tended to be associated with reduced OA risk in
women (OR 0.76, p=0.028, for knee OA; OR=0.84, p=0.076 for hip OA), but
with increased risk of hip OA in men (OR 1.28; p=0.029). Women carrying
two copies of the rs1062033 G-allele and no copies of the rs2234693
C-allele were at particular risk for knee OA, with an OR of 1.61 (p=0.006).
The rs1062033 GG genotype associated with increased OA risk was also
associated with reduced expression of CYP19A1 in bone (p=0.036).
Conclusions: Common genetic variations of the aromatase and estrogen re-
ceptor α genes CYP19A1 and ESR1 are associated with the risk of severe OA
of the large joints of the lower limb in a sex-speciﬁc manner. These results
are consistent with the hypothesis that estrogen activity inﬂuences the
development of large-joint OA. The CYP19A1 SNP rs1062033, or a SNP in
linkage disequilibrium with it, may mediate its effect on OA susceptibility
by regulating the expression of CYP19A1.
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Purpose: Chronic Widespread Pain (CWP) is prevalent in approximately
10% of the general population and may result from inadequately treated
chronic focal pain problems such as osteoarthritis (OA) and inﬂuences
human well-being. The prognosis of CWP patients appears to be poor and
it is associated with increased consumption of health care and working
disability. CWP is regarded to be a complex trait, meaning that both
environmental and genetic factors play a role in the etiology. Twins studies
have estimated a heritability of 48-54% for CWP. So far candidate gene
studies have not been able to discover genes involved in the pathogenesis
of CWP, possibly due to small sample sizes. Meta-analysis of Genome Wide
Association Studies (GWAS) from several population based cohort studies
is a hypothesis-free and more robust state-of-the-art approach to identify
genetic risk factors. The objective of this study was to identify genes
involved in CWP by means of a large-scale GWAS meta-analysis.
Methods: CWP is deﬁned as pain present in at least both sides of the
body, pain above and below the waist, and axial skeletal pain (the FMS
criteria of the American College of Rheumatology (ACR)). We conducted
